Physician profile
Barry Streit
NPI 1033121116
$18,807.40
in general payments reported to CMS, 2019-2025
43 companies · $2,962 in 2025
The $2,962 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,846 · 2020: $2,377 · 2021: $3,274 · 2022: $2,247 · 2023: $2,989 · 2024: $2,112 · 2025: $2,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,041 · Education: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,040.71 |
| Education | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,130.21 | 2019-2025 | Airsupra, Fasenra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,220.64 | 2019-2025 | Jardiance, Ofev, Stiolto Respimat |
| Glaxosmithkline, LLC. | $2,645.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Novo Nordisk INC | $1,406.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $844.64 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $786.83 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $753.85 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Mylan Specialty L.P. | $630.46 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $567.64 | 2020-2021 | |
| Amgen INC. | $518.89 | 2020-2025 | Repatha, Evenity, Krystexxa |
| Paratek Pharmaceuticals, INC. | $342.28 | 2020-2025 | Nuzyra |
| Verona Pharma, INC. | $286.22 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.15 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $231.56 | 2019-2024 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $221.18 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $179.79 | 2019-2025 | |
| Abbott Laboratories | $173.18 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sunovion Pharmaceuticals INC. | $165.96 | 2019-2020 | |
| Grifols USA, LLC | $160.31 | 2021-2025 | Prolastin-C Liquid |
| Exact Sciences Corporation | $158.48 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Regeneron Healthcare Solutions, INC. | $141.45 | 2020-2025 | Dupixent |
| Pfizer INC. | $119.42 | 2019-2024 | |
| Insmed, INC. | $76.62 | 2024-2025 | Brinsupri, Arikayce |
| Gilead Sciences, INC. | $62.68 | 2020-2025 | |
| Inspire Medical Systems, INC. | $62.22 | 2025 | Inspire |
| Viiv Healthcare Company | $55.45 | 2024 | Apretude |
| Teva Pharmaceuticals USA, INC. | $55.20 | 2020 | |
| Esperion Therapeutics, INC. | $49.04 | 2020-2025 | Nexletol |
| Viatris Specialty LLC | $48.98 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $48.42 | 2021-2022 | |
| Dexcom, INC. | $47.10 | 2024 | Dexcom G6 Transmitter |
| Irhythm Technologies, INC. | $46.17 | 2024 | Zio Xt Patch, Zio Monitor |
| Agepha Pharma Fz LLC | $44.54 | 2024-2025 | Lodoco |
| Biohaven Pharmaceutical Holding Company LTD. | $41.61 | 2022 | |
| Idorsia Pharmaceuticals US INC | $40.76 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $35.38 | 2019-2021 | |
| Astellas Pharma US INC | $33.25 | 2025 | Veozah |
| United Therapeutics Corporation | $33.00 | 2025 | Tyvaso |
| Genentech USA, INC. | $32.85 | 2019 | |
| Optinose US, INC. | $23.61 | 2025 | |
| Arbor Pharmaceuticals, INC. | $21.35 | 2021 | |
| Philips North America LLC | $18.79 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Streit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.